- Home
- BIOX vs MNPR Comparison
BIOX vs MNPR Comparison
Compare BIOX & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIOX
- MNPR
- Stock Information
- Founded
- BIOX 2001
- MNPR 2014
- Country
- BIOX Argentina
- MNPR United States
- Employees
- BIOX N/A
- MNPR N/A
- Industry
- BIOX Agricultural Chemicals
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- BIOX Industrials
- MNPR Health Care
- Exchange
- BIOX Nasdaq
- MNPR Nasdaq
- Market Cap
- BIOX 275.1M
- MNPR 249.5M
- IPO Year
- BIOX N/A
- MNPR 2019
- Fundamental
- Price
- BIOX $4.80
- MNPR $30.01
- Analyst Decision
- BIOX Strong Buy
- MNPR Strong Buy
- Analyst Count
- BIOX 4
- MNPR 5
- Target Price
- BIOX $8.63
- MNPR $59.50
- AVG Volume (30 Days)
- BIOX 144.3K
- MNPR 20.8K
- Earning Date
- BIOX 05-21-2025
- MNPR 05-13-2025
- Dividend Yield
- BIOX N/A
- MNPR N/A
- EPS Growth
- BIOX N/A
- MNPR N/A
- EPS
- BIOX N/A
- MNPR N/A
- Revenue
- BIOX $383,293,344.00
- MNPR N/A
- Revenue This Year
- BIOX N/A
- MNPR N/A
- Revenue Next Year
- BIOX $7.55
- MNPR N/A
- P/E Ratio
- BIOX N/A
- MNPR N/A
- Revenue Growth
- BIOX N/A
- MNPR N/A
- 52 Week Low
- BIOX $3.51
- MNPR $1.72
- 52 Week High
- BIOX $11.86
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- BIOX 54.72
- MNPR 34.22
- Support Level
- BIOX $4.31
- MNPR $28.40
- Resistance Level
- BIOX $5.18
- MNPR $36.82
- Average True Range (ATR)
- BIOX 0.31
- MNPR 3.29
- MACD
- BIOX 0.03
- MNPR -0.79
- Stochastic Oscillator
- BIOX 56.65
- MNPR 13.50
About BIOX Bioceres Crop Solutions Corp.
Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. Some of the products offered by the company include fertilizers, inoculants, adjuvants, crop protection solutions, and seeds among others. Its operating segments are crop protection, which derives key revenue, seed and integrated products, and crop nutrition. Geographically, the majority of the company's revenue is generated from Argentina and the rest from Brazil, North America, Latin America, and other regions.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.